Intuitive has received the US Food & Drug Administration (FDA) approval for its SP SureForm 45 stapler for use with the da Vinci SP surgical system.
The stapler is indicated for use in thoracic, colorectal, and urologic procedures.
The SP SureForm 45 stapler, equipped with the medical device company’s SmartFire technology, continuously monitors tissue compression before and during firing.
Its real-time optimisation feature ensures staple line integrity and minimises the risk of tissue damage, even with varying thicknesses.
The technology aims to improve surgical outcomes by enhancing precision.
The FDA approval indicates a significant development in robotic-assisted surgery, facilitating enhanced precision and efficiency in these medical fields.
Intuitive chief medical officer Myriam Curet said: “Being able to use a SureForm 45 stapler in single-port robotic surgery helps provide surgeons with more control of their procedures from the da Vinci surgeon console, without the need to rely on an assistant to fire a stapler.
“This kind of control can help save valuable operating time.”
Based in Sunnyvale, California, Intuitive is a medical device company focused on minimally invasive care and robotic surgery.
The company’s portfolio includes the da Vinci surgical system and the Ion endoluminal system, which together aim to optimise care delivery and support superior patient outcomes.
The da Vinci SP system provides surgeons with robotic-assisted technology, enabling surgical approaches that can lead to faster patient recovery and reduced postoperative pain.
The system enables control of up to three wristed instruments and a high-definition, three-dimensional camera, all entering through a single access point.
It has been approved for various procedures in the US, Europe, Japan, Korea, and Taiwan.
However, the SP SureForm 45 stapler is cleared only for thoracic, colorectal, and urology procedures, excluding transoral otolaryngology.
